Oncology

Neurogene raises USD 68.5 Million for rare neurological diseases Neurogene netted USD 68.5 million to advance multiple gene therapy programs in its series A round. The idea is to take its major programs into IND-enabling studies for Aspartylglucosaminuria (AGU) and a rare form of Charcot-Marie Tooth disease with clinical trials. It receives the funding from Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management and Redmile Group. AbbVie and Teneobio sign USD 90 Million agreement for multiple myeloma Teneobio and AbbVie are signing an agreement to develop the bispecific antibody that aims BCMA and CD3. The Big Pharma is giving USD 90 mil...